MetaCap

Elicio Therapeutics (ELTX) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spero Therapeutics (SPRO) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 67.9% versus a loss of 82.8%. Over five years, SPRO leads with a -95.1% price change compared with -96.1% for ELTX. Spero Therapeutics is the larger company by market cap ($43.2 million vs $41.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELTX-82.84%SPRO-67.88%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
ELTX-96.46%SPRO-95.50%
+5%-48%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELTX versus SPRO key metrics
MetricELTXSPRO
Share price$1.45$0.742
Market cap$41.05M$43.23M
1-day change-3.33%-10.20%
YTD return-81.78%-68.15%
1-year return-82.84%-67.88%
5-year return-96.13%-95.09%
EPS (TTM)$-1.81$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$66.80M
Revenue growth (YoY)—+39.24%
Net income (latest FY)$-39.57M$8.57M
Operating margin—9.45%
Net margin—12.83%
52-week high$16.00$3.08
52-week low$1.25$0.73
Distance from 52-week high-90.94%-75.91%
Analyst consensusstrong_buynone
Avg. price target upside+842.76%+573.85%
Average volume324.71K530.46K
Shares outstanding28.31M58.26M
Employees3325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SPRO has outperformed ELTX by 15.0 percentage points over the past year.

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

ELTX vs SPRO FAQ

Which is bigger, Elicio Therapeutics or Spero Therapeutics?

Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $41.05M for Elicio Therapeutics (ELTX).

Which stock has performed better over the past year, ELTX or SPRO?

SPRO returned -67.88% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Elicio Therapeutics and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons